Upstream therapeutic strategies of valsartan and fluvastatin on hypertensive patients with non ‐permanent atrial fibrillation
ConclusionsCCB plus fluvastatin and valsartan can reduce the recurrence rate of non ‐permanent AF and to delay the progression from non‐permanent AF to permanent AF in patients with hypertension. The combined application of valsartan and fluvastatin is more effective than valsartan or CCB alone in the upstream therapies of AF. (Source: Cardiovascular Therapeutics)
Source: Cardiovascular Therapeutics - January 28, 2019 Category: Cardiology Authors: Zhiqiang Zhao,
Xiaowei Niu,
Zhaojie Dong,
Wenwei Qi,
Enzhao Liu,
Tong Liu,
Lifeng Li,
Yingzi Liang,
Guangping Li Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
Fasudil exerts a cardio ‐protective effect on mice with coxsackievirus B3‐induced acute viral myocarditis
ConclusionsROCK pathway inhibition was cardio ‐protective in viral myocarditis with increased survival, decreased viral replication, and inflammatory response. These findings suggest that Fasudil might be a potential therapeutic agent for patients with viral myocarditis. (Source: Cardiovascular Therapeutics)
Source: Cardiovascular Therapeutics - January 28, 2019 Category: Cardiology Authors: Kezhi Dai,
Yaoyao Wang,
Sichao Tai,
Huajing Ni,
Hao Lian,
Yan Yu,
Weifang Liao,
Cheng Zheng,
Qing Chen,
Aarti Kuver,
Jia Li Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
Combination therapy with cilostazol and pravastatin improves antiatherogenic effects in low ‐density lipoprotein receptor knockout mice
ConclusionsOur results suggest that combination therapy with pravastatin and cilostazol exerts beneficial effects by decreasing atherosclerotic lesion progression and improving the pro ‐inflammatory state in the vascular endothelium. These effects are mediated by the reduction in adhesion molecule expression, immune cell infiltration, and cytokine levels and the antiatherosclerotic modulation of serum cholesterol levels. Therefore, we conclude that combined treatment with pravas tatin and cilostazol may be a more effective antiatherosclerotic strategy than treatment with either agent alone. (Source: Cardiovascular Therapeutics)
Source: Cardiovascular Therapeutics - January 28, 2019 Category: Cardiology Authors: Kyung ‐Yeon Park,
Tae‐Hwe Heo Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
The incidence of atrial fibrillation with trastuzumab treatment: A systematic review and meta ‐analysis
ConclusionsAtrial fibrillation incidence in breast cancer patients receiving trastuzumab was around 1.2%. It was not influenced by the formulation of trastuzumab, the additional use of neoplastic agents, anthracycline exposure status, or concurrent radiotherapy. (Source: Cardiovascular Therapeutics)
Source: Cardiovascular Therapeutics - January 28, 2019 Category: Cardiology Authors: Ming Yuan,
Gary Tse,
Zhiwei Zhang,
Xu Han,
William K. K. Wu,
Guangping Li,
Yunlong Xia,
Tong Liu Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
Calcium channel blockers are associated with improved survival and lower cardiovascular mortality in patients with renovascular disease
ConclusionsCalcium channel blockers are associated with significantly increased survival and lower cardiovascular mortality particularly in patients with moderate RAS disease. (Source: Cardiovascular Therapeutics)
Source: Cardiovascular Therapeutics - January 28, 2019 Category: Cardiology Authors: Harshal Deshmukh,
Emma Barker,
Thineshkrishna Anbarasan,
Daniel Levin,
Samira Bell,
Miles D. Witham,
Jacob George Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
The modifying effect of the MTHFR genotype on the association between folic acid supplementation and pulse wave velocity: Findings from the CSPPT
ConclusionIn a subgroup of Chinese hypertensive patients who had received 5 ‐year antihypertensive therapy, increases in folate status were associated with higher reductions in PWV, and individuals with the CC genotype showed greatest PWV response to folic acid supplementation. (Source: Cardiovascular Therapeutics)
Source: Cardiovascular Therapeutics - January 28, 2019 Category: Cardiology Authors: Xin Yang,
Minghua Zhang,
Rensheng Song,
Changfu Liu,
Yong Huo,
Geng Qian Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
Effects of tranexamic acid on short ‐term and long‐term outcomes of on‐pump coronary artery bypass grafting: Randomized trial and 7‐year follow‐up
ConclusionsTranexamic acid significantly decreased postoperative bleeding and allogeneic transfusion in patients undergoing on ‐pump CABG. The 7‐year follow‐up suggested that the use of TXA was safe and might play a potential role in the prevention of long‐term myocardial infarction. (Source: Cardiovascular Therapeutics)
Source: Cardiovascular Therapeutics - January 28, 2019 Category: Cardiology Authors: Yu Zhang,
Xurong Gao,
Su Yuan,
Jingfei Guo,
Huanran Lv,
Yong Zhou,
Yuefu Wang,
Hongwen Ji,
Guyan Wang,
Lihuan Li,
Jia Shi Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
Effects of serial phlebotomy on vascular endothelial function: Results of a prospective double ‐blind randomized study
ConclusionsFour serial phlebotomy procedures over six months with or without intravenous iron supplementation did not alter vascular endothelial function in the brachial artery when compared with sham phlebotomy. (Source: Cardiovascular Therapeutics)
Source: Cardiovascular Therapeutics - January 28, 2019 Category: Cardiology Authors: Qurat ‐ul‐ain Jelani,
Bhisham Harchandani,
Ritchard G. Cable,
Yu Guo,
Hua Zhong,
Timothy Hilbert,
Jonathan D. Newman,
Stuart D. Katz Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
Hydromorphine postconditioning protects isolated rat heart against ischemia ‐reperfusion injury via activating P13K/Akt/eNOS signaling
ConclusionsThese findings suggest that hydromorphine postconditioning may protect isolated rat heart against reperfusion injury via activating P13K/Akt/eNOS signaling. (Source: Cardiovascular Therapeutics)
Source: Cardiovascular Therapeutics - January 28, 2019 Category: Cardiology Authors: Qing Liu,
Zhengfen Li,
Yuexin Liu,
Qiuxia Xiao,
Xuan Peng,
Qi Chen,
Rui Deng,
Zhiwei Gao,
Fengxu Yu,
Ying Zhang Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
Issue Information
Cardiovascular Therapeutics, Volume 36, Issue 6, December 2018. (Source: Cardiovascular Therapeutics)
Source: Cardiovascular Therapeutics - January 28, 2019 Category: Cardiology Tags: ISSUE INFORMATION Source Type: research
Activation of AMPK alleviates cardiopulmonary bypass ‐induced cardiac injury via ameliorating acute cardiac glucose metabolic disorder
In conclusion, it was suggested in this study that preactivation of AMPK by AICAR improved myocardial glucose uptake by promoting AS160 dependent myocardial membrane GLUT‐4 translocation, which ultimately provided a potent cardioprotective effect. (Source: Cardiovascular Therapeutics)
Source: Cardiovascular Therapeutics - January 28, 2019 Category: Cardiology Authors: Zhifa Wang,
Yukun Cao,
Qiang Yin,
Yuehu Han,
Yunya Wang,
Guocheng Sun,
Hailong Zhu,
Ming Xu,
Chunhu Gu Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
Hydromorphine postconditioning protects isolated rat heart against ischemia ‐reperfusion injury via activating P13K/Akt/eNOS signaling
ConclusionsThese findings suggest that hydromorphine postconditioning may protect isolated rat heart against reperfusion injury via activating P13K/Akt/eNOS signaling. (Source: Cardiovascular Therapeutics)
Source: Cardiovascular Therapeutics - January 28, 2019 Category: Cardiology Authors: Qing Liu,
Zhengfen Li,
Yuexin Liu,
Qiuxia Xiao,
Xuan Peng,
Qi Chen,
Rui Deng,
Zhiwei Gao,
Fengxu Yu,
Ying Zhang Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
Activation of AMPK alleviates cardiopulmonary bypass induced cardiac injury via ameliorating acute cardiac glucose metabolic disorder
In conclusion, it was suggested in this study that pre‐activation of AMPK by AICAR improved myocardial glucose uptake by promoting AS160 dependent myocardial membrane GLUT‐4 translocat ion, which ultimately provided a potent cardioprotective effect.This article is protected by copyright. All rights reserved. (Source: Cardiovascular Therapeutics)
Source: Cardiovascular Therapeutics - January 11, 2019 Category: Cardiology Authors: Zhifa Wang,
Yukun Cao,
Qiang Yin,
Yuehu Han,
Yunya Wang,
Guocheng Sun,
Hailong Zhu,
Ming Xu,
Chunhu Gu Tags: Original Research Article Source Type: research
Hydromorphone Postconditioning Protects Isolated Rat Heart against Ischemia ‐Reperfusion Injury via Activating P13K/Akt/eNOS Signaling
ConclusionsThese findings suggest that hydromorphone postconditioning may protect isolated rat heart against reperfusion injury via activating P13K/Akt/eNOS signaling.This article is protected by copyright. All rights reserved. (Source: Cardiovascular Therapeutics)
Source: Cardiovascular Therapeutics - December 29, 2018 Category: Cardiology Authors: Qing Liu,
Zhengfen Li,
Yuexin Liu,
Qiuxia Xiao,
Xuan Peng,
Qi Chen,
Rui Deng,
Zhiwei Gao,
Fengxu Yu,
Ying Zhang Tags: Original Research Article Source Type: research
